Phase II clinical trial - Recherches "plusieurs pathologies"
CA209-848
Recherches "plusieurs pathologies"
Essai clinique fermé
Public cible
Adulte
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Description de l'essai
The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H).
Liens utiles
EMANUELA ROMANO
Investigateur principal